Core Laboratories (NYSE:CLB) Shares Gap Down – Here’s Why

Core Laboratories Inc. (NYSE:CLB) gapped down prior to trading on Thursday . The stock had previously closed at $17.30, but opened at $16.12. Core Laboratories shares last traded at $14.3930, with a volume of 258,313 shares changing hands.

Core Laboratories News Roundup

Here are the key news stories impacting Core Laboratories this week:

• Positive Sentiment: Board declared a quarterly dividend of $0.01/share (?0.3% yield) payable June 1 — a token return of capital that provides a small floor for income-focused holders. CORE LAB REPORTS FIRST QUARTER 2026 RESULTS
• Positive Sentiment: Company repurchased 51,781 shares for ~$0.9M — modest buyback that marginally supports the share count. CORE LAB REPORTS FIRST QUARTER 2026 RESULTS
• Neutral Sentiment: Reported Q1 EPS of $0.06, which matched consensus, and revenue of $121.8M roughly in line with expectations — not a surprise to models but lacked upside. Core Laboratories Earnings / Transcript
• Neutral Sentiment: Analyst commentary and comparisons (e.g., DTI vs CLB) are circulating as investors reassess relative value in the oilfield services group. DTI or CLB: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Management cut Q2 2026 EPS guidance to $0.060–$0.120 vs. consensus ~$0.15, and set revenue guidance $123M–$131M (consensus ~ $127.8M) — the lowered guide is the primary catalyst for the negative price move. Core Laboratories Posts Flat Q1 2026 Results Amid Disruptions
• Negative Sentiment: Key underlying metrics showed deterioration — EPS ex-items fell sharply (ex-items EPS down 72% sequential), free cash flow essentially flat at $0.5M, GAAP loss per share of $0.02, and net debt increased by ~$3.9M — raises execution and cash-generation concerns. CORE LAB REPORTS FIRST QUARTER 2026 RESULTS

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Core Laboratories in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $12.50.

Core Laboratories Price Performance

The company has a debt-to-equity ratio of 0.41, a current ratio of 2.02 and a quick ratio of 1.51. The business’s 50-day moving average price is $16.74 and its two-hundred day moving average price is $16.69. The firm has a market cap of $670.26 million, a price-to-earnings ratio of 21.81, a P/E/G ratio of 3.25 and a beta of 1.15.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Wednesday, April 29th. The oil and gas company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The firm had revenue of $121.80 million during the quarter, compared to analyst estimates of $122.99 million. Core Laboratories had a return on equity of 12.18% and a net margin of 6.04%.Core Laboratories’s quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.14 earnings per share. Core Laboratories has set its Q2 2026 guidance at 0.060-0.120 EPS. On average, research analysts forecast that Core Laboratories Inc. will post 0.57 EPS for the current fiscal year.

Core Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Monday, May 11th will be given a $0.01 dividend. The ex-dividend date of this dividend is Monday, May 11th. This represents a $0.04 annualized dividend and a yield of 0.3%. Core Laboratories’s dividend payout ratio (DPR) is currently 5.97%.

Hedge Funds Weigh In On Core Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWA Asset Management Group LLC purchased a new position in Core Laboratories during the 4th quarter worth approximately $9,978,000. Pacific Ridge Capital Partners LLC purchased a new stake in Core Laboratories in the 3rd quarter worth about $525,000. Intech Investment Management LLC lifted its stake in Core Laboratories by 6.7% in the 3rd quarter. Intech Investment Management LLC now owns 44,504 shares of the oil and gas company’s stock worth $550,000 after acquiring an additional 2,801 shares in the last quarter. FourThought Financial Partners LLC acquired a new stake in Core Laboratories during the 3rd quarter worth about $310,000. Finally, Fox Run Management L.L.C. grew its stake in Core Laboratories by 5.9% during the 3rd quarter. Fox Run Management L.L.C. now owns 18,531 shares of the oil and gas company’s stock valued at $229,000 after acquiring an additional 1,038 shares in the last quarter. Institutional investors and hedge funds own 97.81% of the company’s stock.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.